Last reviewed · How we verify
Resin modified glass ionomer cement
At a glance
| Generic name | Resin modified glass ionomer cement |
|---|---|
| Also known as | RMGIC, FujiCEM Evolve (GC, Tokyo, Japan) |
| Sponsor | Nourhan M.Aly |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Assessment of Alkasite Restorative Material Versus Resin Modified Glass Ionomer in Class V Cavities: A Clinical Trial (NA)
- Lesion Sterilization and Tissue Repair Antibiotic Paste Versus Zinc Oxide and Eugenol Pulpectomy for Treatment of Primary Molars With Pulp Necrosis (PHASE1, PHASE2)
- Traditional vs. Minimally Invasive Decay Treatments in Primary Molars: An 18-month Split-mouth Randomized Study (NA)
- Gingival Health After Zirconia Versus Stainless Steel Crowns in Children (NA)
- Clinical and Radiographic Assessment of Neo Putty MTA Versus Formocresol Used in Vital Pulpotomy of Mandibular Primary Molars (NA)
- Evaluation of Different Cementation Materials Used in Prefabricated Pediatric Zirconia Crowns (NA)
- LT Comparative Effectiveness of 2 Caries Treatments (NA)
- Comparison of Post Cementation Sensitivity Between RMGIC and GIC as Luting Materials in a Randomized Clinical Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Resin modified glass ionomer cement CI brief — competitive landscape report
- Resin modified glass ionomer cement updates RSS · CI watch RSS
- Nourhan M.Aly portfolio CI